AngioDynamics helps SIRF’s Discovery Campaign to expand minimally invasive medicine The Society of Interventional Radiology Foundation’s Discovery marketing campaign will benefit from a $500,000 pledge by new ‘Futurist’ level supporter, medical device producer AngioDynamics. ‘Initiatives of this kind continue steadily to reinforce possibilities for expenditure in the specialty’s future, with funding that supports grants, study consensus panels, registries, clinical trials and educational development,’ said John A. Kaufman, M www.himcolin gel himcolin.org .D., FSIR, chair of the SIR Foundation board of directors.

http://himcolin.org/

In July 2010, the FDA reported that a safety overview of ARBs will be performed after a released study found a small increased risk of cancer in sufferers taking an ARB compared to those patients not taking an ARB.D., deputy director for basic safety in the Division of Cardiovascular and Renal Medicines in the FDA’s Middle for Drug Evaluation and Study. Related StoriesOvarian cancer sufferers with a brief history of oral contraceptive make use of have better outcomesMD Anderson study reveals why chemotherapy medications not effective for most pancreatic cancers patientsCornell biomedical engineers develop ‘super natural killer cells’ to destroy cancers cells in lymph nodesARBs are medicines used alone or in combination with other medications to take care of high blood circulation pressure and various other heart-related conditions.